Relmada Therapeutics ( (RLMD) ) has shared an announcement.
Relmada Therapeutics, a biotechnology company focusing on CNS and metabolic disorders, announced plans to discontinue the Reliance II and Relight Phase 3 studies of its REL-1017 program following a recent data review. The company is exploring strategic alternatives to maximize shareholder value, including potential asset sales or mergers, while continuing the development of its REL-P11 metabolic disease treatment. This move signifies a strategic shift to optimize resources and explore new opportunities.
See more insights into RLMD stock on TipRanks’ Stock Analysis page.